Alector, Inc.

Alector is headquartered in South San Francisco, California, and its business is managed from the United States. The company’s current revenue base is tied primarily to the GSK collaboration, with the agreement explicitly splitting commercialization rights between the United States and the rest of the world. In the United States, Alector and GSK would share profits and losses equally on covered products, while outside the United States GSK would handle commercialization and Alector would receive tiered royalties. Because the company is still clinical-stage, geography matters more through partner rights, development responsibilities, and future commercialization economics than through a broad operating footprint. The company also depends on global third-party manufacturers and collaborators, which adds cross-border execution and regulatory complexity.

Alector faces the classic risks of a clinical-stage biotechnology company: no approved products, no product sales, and a long path to proving clinical efficacy and safety. Its business depends heavily on third-party collaborators and manufacturers, so delays, termination rights, quality issues, or underperformance by partners could materially slow development or disrupt supply. The company also expects to continue incurring losses and will need additional capital in the future, creating financing and dilution risk if markets are weak or trial results disappoint. In neurodegenerative disease, clinical endpoints are difficult to move, patient selection is challenging, and regulatory approval standards are high, which increases the chance of late-stage failure. Because a large share of future value is tied to the GSK agreement, any change in that relationship would have an outsized impact on economics and strategic flexibility.